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Bothrops andianus is a venomous snake found in the area of Machu Picchu (Peru). Its
venom is not included in the antigenic pool used for production of the Peruvian anti-
bothropic anti-venom. B. andianus venom can elicit many biological effects such as
hemorrhage, hemolysis, proteolytic activity and lethality. The Peruvian anti-bothropic
anti-venom displays consistent cross-reactivity with B. andianus venom, by ELISA and
Western Blotting and is also effective in neutralizing the venom’s toxic activities.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.Snake bites represent an important health problem in
Peru, especially to the east of the Andes in the High Forest
(600–3500 m altitude) and Tropical Rain Forest (<600 m
altitude) (Ministério de Salúd Peru, 2004). These regions
are known for containing the major Peruvian snake species
and most diversiﬁed ophidian population. The Instituto
Nacional de Salud (INS), located in Lima, Peru has been
producing commercial anti-venoms since 1978 (Ministério
de Salúd Peru, 2004). The Peruvian anti-bothropic poly-
valent anti-venom (PABA), used to treat envenomationsPABA, Peruvian anti-
erum albumin; PBS,
se; MHD, Minimum
MC, Dimethylcasein;
5; fax: þ55 31 3441
-Olórtegui).
lsevier OA license.involving Bothrops complex (Bothrops and Bothrocophias
genera), is a whole IgG preparation produced from horse
plasma previously immunized with an antigenic pool
consisting of Bothrops atrox (50%), Bothrops pictus, Bothrops
barnetti, Bothrops brazili and Bothrocophias hyoprora (12.5%
each) venoms (Laing et al., 2004; Rojas et al., 2005;
Theakston and Warrell, 1991). Besides neutralizing the
most severe toxic effects induced by envenomation
involving snakes from the antigenic pool, (Laing et al.,
2004; Rojas et al., 2005) the preclinical assessment of
anti-venom’s efﬁcacy against venoms from other medically
important species would be useful in Latin America for
improving anti-venom production (Gutierrez et al., 2009).
This work describes the preclinical evaluation of the
neutralizing capacity of PABA against lethality, hemor-
rhagic, proteolytic, and PLA2 effects of Bothrops andianus’
venom. B. andianus is a venomous snake found in the
southern mountains of Peru and Bolivia and its venom is
F. S. Schneider et al. / Toxicon 60 (2012) 1018–1021 1019not included in PABA production. In Peru, B. andianus is
found in the areas (departments) of Cuzco and Puno, at
elevations of 1800–3300 m (Ministério de Salúd Peru,
2004). Its geographical distribution overlaps Machu Pic-
chu area, a UNESCO World Heritage Site (UNESCO, 2012),
which is an important touristic attraction and receives
more than 600,000 tourists per year, increasing the risks of
accidents involving this snake. In Peru, the snakes of genus
Bothrops are responsible for 80% of accidents and approx-
imately 6.5% of these accidents are registered in the Cuzco
and Puno Departments (Ministério de Salúd Peru, 2004).
For the experiments, male and female Swiss mice
(18–22 g) were maintained in the Centro de Bioterismo of
Instituto de Ciências Biológicas of Universidade Federal de
Minas Gerais (UFMG), Brazil. All animals receivedwater and
food ad libitum under controlled environmental conditions.
The experimental protocols were approved by the Ethics
Committee in Animal Experimentation (CETEA/UFMG).
PABA, crude venoms from B. andianus, and antigenic pool
species were provided by INS. Venoms were kept at 20 C
and anti-venom at 4 C temperature as indicated on their
prescription. The protein content in crude venoms and anti-
venoms were determined according to Bradford’s method
(1976) using BSA (Sigma Chemicals) as standard.
Lethality of B. andianus venom was assessed by the
intra-peritoneal (i.p.) route. Groups of four mice were
injected with increasing amounts of venom (34.6 mg–72 mg/
mouse), dissolved in 0.5 ml of PBS–BSA 0.01% solution, pH
7.4. Twenty four hours later, deaths were counted and LD50
was calculated using Probit analysis (95% conﬁdence)
(Finney, 1971).
The hemorrhagic activity was assayed as described in
Kondo et al. (1960) and modiﬁed by Gutierrez et al. (1985).
Five different doses (3.72 mg; 5.2 mg; 7.29 mg; 10.2 mg;
14.28 mg) of crude venom were inoculated subcutaneously
into dorsal shaved skin of mice in 0.1 ml NaCl 0.9%. Two
hours later, mice were sacriﬁced by cervical dislocation and
back skin was totally removed in order to measure the area
of the hemorrhagic lesion. MHD was deﬁned by the dose
causing a lesion with a diameter of 10 mm.
PLA2 activity was measured using an indirect hemolytic
assay (Gutierrez et al., 1988). Increasing concentrations of B.
andianus venom (from 0.004 mg up to 10 mg) were prepared
in a ﬁnal volume of 15 ml in PBS and added to 2 mmwells in
agarose gel plates (0.8% in PBS, pH ¼ 8.1, containing 1.2%
sheep erythrocytes, 1.2% egg yolk and 100mMCaCl2). Plates
were incubated at 37 C for 18 h and the diameters of the
hemolytic haloes were measured. In controls, 15 ml of PABA
was used. One unit (Minimum PLA2 Doses-MPD) corre-
sponds to a minor concentration of venomwhich produced
a hemolytic halo of 10 mm diameter. Experiments were
conducted in triplicate.
Proteolytic activity was measured with dimethylcasein
(Sigma) as described in Lin et al. (1969) with the modiﬁ-
cations described in Sanchez et al. (2000). Dilutions cor-
responding to 5, 10, 20 and 40 mg of venom were used and
absorbance values were determined at 340 nm. One unit
was deﬁned as DA 340 nm/min. Activity was expressed
relative to protein concentration (mg).
The anti-venom potency was determined by mixing
5LD50 of B. andianus venomwith 12.5, 25, 50, 100 or 200 mlof PABA and incubating for 1 h at 37 C followed by i.p.
injection in 5 groups of 4 mice. Median effective dose
(ED50) was calculated from the number of deaths within
24 h of injection of the venom/anti-venom mixture using
Probit analysis as described above. The ED50 was expressed
as ml anti-venom/mg of venom needed to prevent death in
50% of the injected mice.
To determine the neutralization of hemorrhagic activity,
PABAwas incubated with either 3MHD or 5MHD for 30min
at 37 C according to manufacturer’s instructions (1 mL of
serum to 2.5 mg of venom) and inoculated in different
groups of 3 Swiss male mice (18–22 g) as described above.
Positive and negative control groups, each consisting of 2
mice were treated with venom alone (5MHD) or anti-
venom, respectively. Two hours later, mice were eutha-
nized and the hemorrhage was measured (Kondo et al.,
1960; Sanchez et al., 1992).
Inhibition of PLA2 activity of B. andianus venom by PABA
was conducted as described by Gutierrez et al. (1998). Two
MPD of venom were incubated with 13, 6.5 and 3.25 ml of
anti-venom for 30 min at 37 C, and 15 ml of each mixture
added in triplicate towells in agarose gels. Neutralization of
venom was checked by the absence of halos on the plate’s
surface.
Inhibition of dimethylcasein hydrolysis by PABA was
estimated by incubation (30 min at 37 C) of a ﬁxed
concentration of B. andianus venom with increasing
amounts of anti-venom (ml). After incubation the mixtures
were tested as described before. The neutralizing ability of
anti-venom is expressed as the quantity of anti-venom able
to neutralize 50% of proteolytic activity obtained by 1mg of
venom.
For the immunological assays (ELISA and Western
Blotting assays), Falcon ﬂexible micro titration plates were
used (Becton Dickinson France S.A). The plates were coated
overnight at 5 C with 100 ml of a 5 mg/ml solution of the
crude venoms (B. andianus, B. atrox, B. barnetti, B. brazili, B.
pictus and B. hyoprora) in 0.02M sodium bicarbonate buffer,
pH 9.6. The assays were performed as described previously
by Chávez-Olórtegui et al. (1991). Absorbance values were
determined at 492 nm with a Biorad 680 Microplate
Reader. All measurements were made in triplicate and the
results expressed as the median of two assays. For Western
Blotting the venoms were subjected to electrophoresis
SDS-PAGE (15%) according to Laemmli (1970) in reducing
conditions. The proteins were transferred onto nitrocellu-
lose membranes (Towbin et al., 1979) and blocked with
PBS-Tween 0.3% containing 2% casein. The membranes
were incubated with PABA (1:10,000) for 1 h at room
temperature. Immunoreactive proteins were detected
using anti-horse Sigma IgG conjugated with peroxidase
(1:3000). After washing three times for 5 min with PBS-
Tween 0.05%, blots were developed using DAB/chlor-
onaphthol according to the manufacturer’s instructions.
The LD50 of B. andianus venom determined in this paper
(57.96 mg, Table 1) is similar to the LD50 doses of B. atrox,
49.9 mg/mouse; B. pictus, 58.91 mg/mouse and B. Barnetti,
53.2 mg/mouse (Laing et al., 2004; Rojas et al., 2005).
However, B. brazili venom was three times more potent in
the LD50 assay than the other four Peruvian venoms (Laing
et al., 2004). PABA was effective in neutralizing lethality
Table 1
Biological activities of Bothrops andianus venom and their neutralization
by PABA.
Effect Activity Neutralizatione
(ml anti-venom/
mg venom)
Lethala LD50 ¼ 57.96 mg
(36.02–93.26)
200  0.0
Hemorrhagicb MHD ¼ 4.68 mg  0.20 187.8  6.0
Proteolyticc 68.50 U/mg  1.75 500.0  43.0
PLA2 activityd MPD ¼ 5 mg  2.83 350  40.0
Results are presented as mean  S.D. (n ¼ 4), except in lethality, where
95% conﬁdence limits are included in parentheses.
a LD50 is expressed as the dose of venom (mg) responsible for causing
50% of death in mice (18–22 g) i.p. injected.
b MHD is deﬁned as the amount of venom (mg) causing a 10 mm
diameter spot hemorrhage on skin 2 h after injection.
c Proteolytic activity is expressed as Units/mg of venom. One unit of
speciﬁc activity is deﬁned as DA 340 nm/min.
d Minimum PLA2 Dose (MPD) is deﬁned as the amount of venom
responsible for causing a 10 mm diameter of hemolysis.
e Neutralization corresponds to the quantity of anti-venom able to
neutralize in 50% lethal, hemorrhagic, proteolytic and PLA2 activities ob-
tained by 1 mg of venom.
Fig. 1. (A) ELISA reactivity of Peruvian anti-bothropic serum against Bop-
throps andianus, B. atrox, B. barnetti, B. brazili, B. hyoprora and B. pictus
venoms. Plates were coated with 0.5 mg of each venom per well and cross-
reactivity tested against anti-bothropic anti-venom using serial dilution
from 1:2000 to 1:256,000. Antibodies were detected with anti-horse Sigma
IgG conjugated with peroxidase (1:3000), OPD and H2O2 in citrated buffer.
(B) Western Blotting analysis of Bothrops venoms. 20 mg of each of the
venoms were analyzed by SDS-PAGE under reducing conditions. Lanes
correspond to: (1) B. andianus, (2) B. atrox, (3) B. barnetti, (4) B. brazili, (5)
Bothrocophias hyoprora, (6) B. pictus. The venoms were analyzed against
anti-bothropic anti-venom (1:10,000) and revealed with DAB/
chloronaphthol.
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izing potency (Table 1, ED50 of 200 ml anti-venom/mg
venom). Furthermore, local hemorrhagic activity of B.
andianus venom was evaluated in a mouse model. B.
andianus venom directly induced extra vascular bleeding
on the underside of the skin 2 h after injection. The esti-
matedMHD is 4.68 mg 0.20 (Table 1). The results obtained
concerning the capacity of PABA to neutralize the hemor-
rhagic effect of B. andianus are shown in Table 1. This anti-
venom was efﬁcient in neutralizing the hemorrhagic
activity. MPD using an indirect hemolytic assay and inhi-
bition of PLA2 activity by PABA were measured. PLA2
activity was dose dependent (data not shown) and theMPD
determined in this study was 5.0 mg (S.D.  2.83 mg) (Table
1). PABA was also able to neutralize B. andianus PLA2
activity with a potency of 350  40.0 (ml anti-venom/mg
venom). The proteolytic activity of B. andianus venom was
expressed as DMC units (D340 nm) hydrolyzed per mg of
venom per minute and was found to be 68.5 U/
mg min  1.75 (Table 1). PABA was able to neutralize B.
andianus proteolytic activity with a potency of 200  11.4
(ml anti-venom/mg venom).
Immunological cross-reactivity of PABA against Bothrops
venoms was assessed by both ELISA and western blotting.
For ELISAs, reactivity at different serum dilutions can be
seen in Fig. 1A. Importantly, cross-reactivity with B.
andianus venom and reactivity with B. atrox, B. barnetti and
B. pictus was observed. In this experiment, a weaker reac-
tivity was observed against the venoms from B. pictus and
B. hyoprora. Fig. 1B shows the results of the Western Blot
assay. PABA was able to recognize all of the analyzed
venoms. Regarding B. andianus venom, reactivity against
bands at w14, 25, 50 kDa and higher masses were
observed. There was remarkable reactivity with the
w14 kDa protein compared to the others.
B. andianus venom has toxicological and electrophoretic
proﬁles similar to those of other Peruvian Bothrops sp.
venoms used in the anti-venom production. Thetoxicological proﬁle is also common to Bothropic enveno-
mations characterized by local tissue damage and by
systemic manifestations (White, 2005). The symptoms
observed in animals experimentally envenomed by B.
andianus venom were very similar to other Peruvian
Bothrops venoms (Laing et al., 2004; Rojas et al., 2005). Our
observations ﬁnd that PABA is effective in neutralizing the
most important toxic activities induced by B. andianus
venoms when using an experimental protocol based on
pre-incubation of venom and anti-venom before testing in
experimental systems (Gutierrez et al., 1990; Otero et al.,
1995). Thus, despite the fact that B. andianus venom is
not included in the antigenic pool used in Peru, PABA is
F. S. Schneider et al. / Toxicon 60 (2012) 1018–1021 1021effective against this venom. Our preclinical observations
are in agreement with the report of Rojas et al. (2005),
which shows the efﬁcacy of Peruvian anti-venom in
neutralizing many snake venoms found in Peru.
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